Sentiment-Signal
37,5
Bearisch
Composite Score (0–100)
Insider (25%)
48.9
1 Insider, 12,7M $ Volumen
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Unternehmen & Branche
| Name | Aurinia Pharmaceuticals Inc. |
|---|---|
| Ticker | AUPH |
| CIK | 0001600620 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,14 Mrd. USD |
| Beta | 1,52 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 283,055,000 | 287,202,000 | 2.07 | 751,587,000 | 581,331,000 |
| 2025-09-30 | 10-K | 73,468,000 | 31,551,000 | 0.23 | ||
| 2025-09-30 | 10-Q | 73,468,000 | 31,551,000 | 0.23 | 527,528,000 | 365,771,000 |
| 2025-06-30 | 10-Q | 70,008,000 | 21,513,000 | 0.16 | 502,562,000 | 335,301,000 |
| 2025-06-30 | 10-K | 70,008,000 | 21,513,000 | 0.16 | ||
| 2025-03-31 | 10-Q | 62,465,000 | 23,344,000 | 0.16 | 504,850,000 | 350,190,000 |
| 2025-03-31 | 10-K | 62,465,000 | 23,344,000 | 0.16 | ||
| 2024-12-31 | 10-K | 59,867,000 | 1,429,000 | 0.01 | 550,645,000 | 377,478,000 |
| 2024-09-30 | 10-Q | 67,771,000 | 14,350,000 | 0.10 | 549,361,000 | 388,002,000 |
| 2024-09-30 | 10-K | 67,771,000 | 14,350,000 | 0.10 | ||
| 2024-06-30 | 10-Q | 57,192,000 | 722,000 | 0.01 | 523,529,000 | 364,616,000 |
| 2024-06-30 | 10-K | 57,192,000 | 722,000 | 0.01 | ||
| 2024-03-31 | 10-K | 50,303,000 | -10,749,000 | -0.07 | ||
| 2024-03-31 | 10-Q | 50,303,000 | -10,749,000 | -0.07 | 516,634,000 | 359,476,000 |
| 2023-12-31 | 10-K | 45,095,000 | -26,875,000 | -0.19 | 548,062,000 | 377,954,000 |
| 2023-09-30 | 10-Q | 54,515,000 | -13,447,000 | -0.09 | 555,013,000 | 391,877,000 |
| 2023-09-30 | 10-K | 54,515,000 | -13,447,000 | -0.09 | ||
| 2023-06-30 | 10-K | 41,494,000 | -11,492,000 | -0.08 | ||
| 2023-06-30 | 10-Q | 41,494,000 | -11,492,000 | -0.08 | 548,900,000 | 392,292,000 |
| 2023-03-31 | 10-K | 34,409,000 | -26,206,000 | -0.18 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | TANG KEVIN | Director | Open Market Purchase | 184,208 | 14.22 | 2,619,437.76 | +98,9% | |
| 2026-03-02 | TANG KEVIN | Director | Open Market Purchase | 83,561 | 14.33 | 1,197,429.13 | +45,2% | |
| 2026-03-02 | TANG KEVIN | Director | Open Market Purchase | 115,792 | 14.21 | 1,645,404.32 | +62,1% | |
| 2026-02-27 | TANG KEVIN | Director | Open Market Purchase | 214,839 | 14.12 | 3,033,526.68 | +114,5% | |
| 2026-02-27 | TANG KEVIN | Director | Open Market Purchase | 1,600 | 14.38 | 23,008.00 | +0,9% | |
| 2026-02-27 | TANG KEVIN | Director | Open Market Purchase | 300,000 | 13.90 | 4,170,000.00 | +157,4% | |
| 2025-08-05 | TANG KEVIN | Director | Open Market Purchase | 200,000 | 11.68 | 2,336,000.00 | +88,2% | |
| 2025-08-04 | TANG KEVIN | Director | Open Market Purchase | 100,000 | 11.34 | 1,134,000.00 | +42,8% | |
| 2025-08-01 | TANG KEVIN | Director | Open Market Purchase | 1,000,000 | 10.12 | 10,120,000.00 | +382,0% | |
| 2025-08-01 | Keenan Greg | Officer, Chief Medical Officer | Open Market Sale | -20,000 | 10.50 | -210,000.00 | -7,9% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.